Your browser is no longer supported. Please, upgrade your browser.
CELG Celgene Corporation daily Stock Chart
Celgene Corporation
IndexS&P 500 P/E15.01 EPS (ttm)6.52 Insider Own0.10% Shs Outstand704.75M Perf Week1.32%
Market Cap68.95B Forward P/E7.79 EPS next Y12.57 Insider Trans-3.22% Shs Float703.78M Perf Month3.16%
Income4.70B PEG0.91 EPS next Q2.62 Inst Own78.60% Short Float1.60% Perf Quarter10.70%
Sales15.77B P/S4.37 EPS this Y4.80% Inst Trans2.13% Short Ratio1.66 Perf Half Y43.59%
Book/sh11.62 P/B8.42 EPS next Y17.06% ROA13.50% Target Price97.00 Perf Year25.86%
Cash/sh10.91 P/C8.96 EPS next 5Y16.43% ROE83.90% 52W Range58.59 - 97.89 Perf YTD52.64%
Dividend- P/FCF10.35 EPS past 5Y26.50% ROI16.50% 52W High-0.06% Beta1.52
Dividend %- Quick Ratio2.70 Sales past 5Y18.70% Gross Margin96.20% 52W Low66.97% ATR0.99
Employees8852 Current Ratio2.80 Sales Q/Q13.80% Oper. Margin42.40% RSI (14)66.08 Volatility1.01% 0.95%
OptionableYes Debt/Eq2.48 EPS Q/Q94.70% Profit Margin30.10% Rel Volume0.59 Prev Close97.15
ShortableYes LT Debt/Eq2.42 EarningsJul 25 BMO Payout0.00% Avg Volume6.79M Price97.83
Recom2.90 SMA202.34% SMA502.90% SMA20014.55% Volume4,034,034 Change0.70%
May-03-19Downgrade Barclays Overweight → Equal Weight $102
Apr-01-19Downgrade William Blair Outperform → Mkt Perform
Apr-01-19Downgrade UBS Buy → Neutral $94 → $102
Apr-01-19Downgrade Atlantic Equities Overweight → Neutral
Feb-01-19Downgrade Jefferies Buy → Hold $95
Jan-04-19Upgrade Robert W. Baird Neutral → Outperform
Jan-04-19Upgrade Goldman Sell → Neutral
Dec-21-18Resumed BTIG Research Neutral
Oct-01-18Initiated Cantor Fitzgerald Overweight $100
Jun-18-18Upgrade Standpoint Research Hold → Buy
May-29-18Reiterated SunTrust Hold $106 → $96
May-23-18Upgrade Bernstein Mkt Perform → Outperform
May-23-18Downgrade Argus Buy → Hold
May-07-18Downgrade RBC Capital Mkts Top Pick → Outperform
Apr-13-18Resumed Morgan Stanley Equal-Weight $93
Mar-26-18Reiterated Goldman Sell $97 → $85
Mar-21-18Resumed JP Morgan Overweight $110
Feb-28-18Reiterated Stifel Buy $130 → $128
Feb-28-18Downgrade SunTrust Buy → Hold
Feb-13-18Upgrade Barclays Equal Weight → Overweight $105
Jun-19-19 05:08PM  This would be the worst-case scenario for health companies, according UBS MarketWatch
04:07PM  Alexion's (ALXN) Ultomiris Gets Approval in Japan for PNH Zacks
12:02PM featured highlights include: Citigroup, DSW, Celgene and Zions Zacks
09:06AM  Big Drugmakers That May Tread the M&A Path After Pfizer Zacks
Jun-18-19 09:25AM  Celgene (CELG) Hits 52-Week High, Can the Run Continue? Zacks
08:55AM  4 High Earnings Yield Stocks to Strengthen Your Portfolio Zacks
07:31AM  The Daily Biotech Pulse: PhaseBio Pumped Up, Eiger Exults On Breakthrough Therapy Designation, Biohaven Slips On Stock Sale Benzinga
Jun-17-19 03:41PM  Novartis (NVS) Announces Promising Data on Tasigna & Hyrimoz Zacks
09:12AM  Regeneron (REGN) Presents Positive Data on Lymphoma Candidate Zacks
Jun-16-19 09:00AM  Is It Too Late to Buy Celgene Stock? Motley Fool
Jun-14-19 09:00AM  Leoplus USA Wins Lyfebulb-Celgene 2019 "Addressing Unmet Needs in MS: An Innovation Challenge" PR Newswire
08:47AM  The Daily Biotech Pulse: Hematology And Rheumatology Conference Presentations Take The Spotlight, Eton In-Licenses Epilepsy Drug NDA Benzinga
08:29AM  Mallinckrodt Presents Encouraging Data on Acthar Gel for RA Zacks
Jun-13-19 05:50PM  Celgene (CELG) Stock Sinks As Market Gains: What You Should Know Zacks
04:12PM  Amgen, Biogen, Gilead and Novo Nordisk have very high capacity for M&A, says Moodys MarketWatch
Jun-12-19 10:19AM featured highlights include: CDW, Bristol-Myers, Celgene, PepsiCo and Northrop Zacks
09:27AM  Biotech Stock Roundup: Celgene Submits MS Drug to FDA, INSY & CBAY Crash Zacks
08:28AM  Boost Your Portfolio's Health With These 3 Big Drug Stocks Zacks
08:15AM  5 Most Valuable Pipeline Drugs in Development -- and the Stocks Poised to Profit Motley Fool
Jun-11-19 06:16PM  Insys Down on Bankruptcy News Amid Increasing Legal Expenses Zacks
12:09PM featured highlights include: Arconic, Amdocs, Tyson Foods, Target and Celgene Zacks
11:26AM  Zynerba Stock Soars on Cannabidiol Patent for Autism Spectrum Disorder InvestorPlace
09:30AM  CELG or VRTX: Which Is the Better Value Stock Right Now? Zacks
08:53AM  Merck (MRK) to Buy Private Biotech Tilos for Up to $773M Zacks
08:34AM  Top 5 ROE Stocks to Buy as US-Mexico Trade Concerns Abate Zacks
12:01AM  Hudson Bay Capital Managements Return, AUM, and Holdings (Part II) Insider Monkey
Jun-10-19 08:38AM  5 Solid Stocks Near 52-Week High Promise to Touch Peak Point Zacks
07:30AM  GT Biopharma Company Update CNW Group
Jun-07-19 05:50PM  Celgene (CELG) Gains But Lags Market: What You Should Know Zacks
05:00PM  Celgene's Filing for Ozanimod Accepted for Review in US/EU Zacks
04:43PM  Getting technical: Stocks love the 'Fed put'; Tesla still in a down trend traders to sell the rally Yahoo Finance Video
01:06PM  2 Dividend Stocks to Buy That Are Better Than 3M Stock InvestorPlace
09:09AM  Novartis Appoints New Pharma Unit Head, Gives Other Updates Zacks
06:58AM  UPDATE 3-Drugmaker Sanofi hires Hudson from Novartis as CEO Reuters
02:16AM  CORRECTED-UPDATE 2-Drugmaker Sanofi appoints Novartis' Hudson as CEO Reuters
01:16AM  Swiss drugmaker Novartis names new drug division head Reuters
Jun-06-19 07:17PM  Management Changes Intended to Boost Bristol-Myers Squibb After Celgene Deal
04:56PM  Celgene & Acceleron's BLA for Luspatercept Accepted by FDA Zacks
04:41PM  Mallinckrodt Down After Agreement with DOJ for Litigation Zacks
03:13PM  5 Healthcare Stocks to Pick Up From the Wreckage InvestorPlace
01:55PM  Top 5 Stocks in the Fight Against Cancer Motley Fool
07:30AM  US FDA and EMA Accept Applications for Ozanimod for the Treatment of Relapsing Forms of Multiple Sclerosis Business Wire
Jun-05-19 04:30PM  The Celgene Merger Looks Secure So Why Is Bristol Under Pressure? Investor's Business Daily
11:46AM  Bristol-Myers Is Getting Bigger. Investors Arent Impressed.
09:00AM  Celgene (CELG) Presents Data on Pipeline Candidates at ASCO Zacks
06:59AM  Bristol-Myers Squibb Announces Post-Closing Leadership Team Business Wire
Jun-04-19 04:24PM  Here's Another Checkmark For Bristol's Looming Celgene Takeover Investor's Business Daily
11:00AM  Celgene Announces Data from Ongoing Studies of Liso-Cel in Patients with Difficult-to-Treat Blood Cancers at ASCO 2019 Business Wire
07:45AM  The Daily Biotech Pulse: ASCO Presentations From Roche, Celgene & More, Edwards Recommends Rejection Of Mini-Tender Offer Benzinga
07:30AM  Celgene Corporation and Acceleron Pharma Announce U.S. FDA Accepts Luspatercept Biologics License Application in Myelodysplastic Syndromes and Beta-Thalassemia Business Wire
Jun-03-19 02:46PM  Why Cancer-Fighting Stocks & ETFs Are Soaring Zacks
09:00AM  Celgene Updated Analysis of JAKARTA2 Fedratinib Study Shows Clinically Meaningful Responses in Patients Previously Treated for Myelofibrosis with Ruxolitinib Business Wire
Jun-02-19 12:45PM  Celgene Presents Data from a Phase 1/2 Clinical Study of Iberdomide in Combination with Dexamethasone in Patients with Relapsed and Refractory Multiple Myeloma at ASCO 2019 Business Wire
Jun-01-19 11:37AM  The Week Ahead In Biotech: ASCO Presentations Pick Up The Pace Benzinga
May-31-19 05:50PM  Celgene (CELG) Stock Moves -0.82%: What You Should Know Zacks
03:16PM  Hedge Funds Have Never Been This Bullish On Celgene Corporation (CELG) Insider Monkey
10:46AM  Epizyme's NDA for Tazemetostat Eyes Epithelioid Sarcoma Cure Zacks
08:10AM  4 High Earnings Yield Stocks to Enhance Your Portfolio Zacks
04:05AM  Novartis (NVS) Reports Positive Phase III Data on Asthma Drug Zacks
May-30-19 07:49AM  Bayer's Aliqopa Gets Breakthrough Therapy Status by FDA Zacks
06:53AM  Should You Invest in the Invesco Dynamic Biotechnology & Genome ETF (PBE)? Zacks
May-29-19 04:11PM  Bristol-Myers Impending Acquisition of Celgene Leaves Analysts Skeptical
10:22AM  Biotech Stock Roundup: AMGN's Nuevolution Buyout, CELG, INCY Drugs' Label Expansion Zacks
08:59AM  Celgene's Revlimid-Rituximab Combo Gets FDA Nod for Lymphoma Zacks
May-28-19 02:08PM  Goldman cuts Gilead to sell CNBC Videos
12:30PM  FDA Approves REVLIMID® (Lenalidomide) In Combination With Rituximab For the Treatment of Adult Patients with Previously Treated Follicular Lymphoma or Marginal Zone Lymphoma Business Wire
10:11AM  Geron Stock Up More Than 50% in 2019 So Far: Here's Why Zacks
May-25-19 09:31AM  Why Is Celgene (CELG) Up 1.4% Since Last Earnings Report? Zacks
May-24-19 02:38PM  The Funded: One Bay Area biotech goes public while another files IPO plans American City Business Journals
02:34PM  Magnetar Capitals Latest Moves Insider Monkey
09:30AM  CELG or VRTX: Which Is the Better Value Stock Right Now? Zacks
08:56AM  5 ROE Stocks to Buy as Trade Concerns Spur Market Volatility Zacks
04:09AM  10 Stock Market Leaders Amid the Trade War Upheaval Investopedia
May-23-19 03:46PM  Novartis Reports Data on Asthma Drug, Update from Annual Meet Zacks
09:19AM  The Zacks Analyst Blog Highlights: Cambrex, Innoviva, Celgene, BioDelivery Sciences International and Unity Biotechnology Zacks
May-22-19 03:42PM  Mallinckrodt (MNK) Down After Filing Suit Against HHS and CMS Zacks
11:34AM  Biotech Stock Roundup: Label Expansion for CELG's Drugs, Setback for IMGN Zacks
10:14AM  3 Years In, Is the "Winners for a Thinking World" Stock Sampler Winning? Motley Fool
07:21AM  5 Biotech Stocks to Gain From Trade Deal Rally on the Horizon Zacks
07:00AM  Bristol-Myers Stock Continues to Slump, but Director Ted Samuels Is Buying Up Shares
May-21-19 06:55PM  John Paulson's Top 5 Buys in the 1st Quarter
11:48AM  5 Winning Ideas for a Thinking World, Plus a 5-Stock Sampler Review Motley Fool
08:13AM  Merck agrees $1bn deal to buy biopharmaceutical company Peloton Financial Times
08:00AM  Celgene and the Multiple Sclerosis Association of America Team Up to Launch MS MindShift for Awareness of Multiple Sclerosis and Brain Health Business Wire
07:46AM  Alexion (ALXN) Stock Up 30.7% YTD: Will the Momentum Stay? Zacks
May-20-19 07:23PM  Prem Watsa Buys Buffett's Red Hat, Boosts Micron in 1st Quarter
06:43PM  George Soros' Top 6 New Buys of the 1st Quarter
06:32PM  4 New Stock Picks From Seth Klarman
02:28PM  Argus Questions Logic Behind Bristol-Myers' Proposed Celgene Buy, Steps To Sidelines Benzinga
09:16AM  Bristol-Myers Stock Is Falling Because the Celgene Merger May Not Make Sense
May-17-19 05:17PM  Celgene Gets EC Nod for Label Expansion of Revlimid, Imnovid Zacks
09:21AM  Q1 13F Roundup: How Buffett, Einhorn, Ackman And Others Adjusted Their Portfolios Benzinga
03:55AM  Carlson Capitals Latest Moves Insider Monkey
May-16-19 05:05PM  Seth Klarman Introduces 7 New Positions in 1st Quarter
10:49AM  Agios' Tibsovo Meets Endpoint in Cholangiocarcinoma Study Zacks
08:30AM  Celgene Receives European Commission Approvals for REVLIMID® (lenalidomide) and IMNOVID® (pomalidomide)-based Triplet Combination Regimens for Patients with Multiple Myeloma Business Wire
08:12AM  4 High Earnings Yield Stocks to Strengthen Your Portfolio Zacks
04:14AM  Adage Capital Managements Latest Portfolio Moves Insider Monkey
May-15-19 05:04PM  Celgene to Highlight New and Updated Hematology and Oncology Clinical Data at Upcoming American Society of Clinical Oncology (ASCO) 2019 Annual Meeting Business Wire
10:49AM  Biotech Stock Roundup: FDA Nod for REGN's Eylea in DR, Tie-Ups & Other Updates Zacks
Celgene Corporation, a biopharmaceutical company, discovers, develops, and commercializes therapies for the treatment of cancer and inflammatory diseases worldwide. It offers REVLIMID, an oral immunomodulatory drug for multiple myeloma (MM), myelodysplastic syndromes (MDS), and mantle cell lymphoma; POMALYST/IMNOVID to treat multiple myeloma; OTEZLA, a small-molecule inhibitor of phosphodiesterase 4 for psoriatic arthritis and psoriasis; and ABRAXANE to treat breast, non-small cell lung, pancreatic, and gastric cancers. The company's products also include IDHIFA for the treatment of adult patients with relapsed or refractory acute myeloid leukemia (rrAML) with an isocitrate dehydrogenase-2 mutation; VIDAZA, a pyrimidine nucleoside analog for intermediate-2 and high-risk MDS, chronic myelomonocytic leukemia, and AML; THALOMID to treat patients with MM; and ISTODAX, an epigenetic modifier. Its preclinical and clinical-stage product candidates include small molecules, biologics, and cell therapies for immune-inflammatory diseases, myeloid diseases, epigenetics, protein homeostasis, and immuno-oncology. The company has agreements with BeiGene, Ltd; Acceleron Pharma, Inc.; Agios Pharmaceuticals, Inc.; bluebird bio, Inc.; Lycera Corp.; Juno Therapeutics, Inc.; and EXSCIENTIA LTD. Celgene Corporation was founded in 1980 and is headquartered in Summit, New Jersey.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
BONNEY MICHAEL WDirectorJun 15Option Exercise0.0037502,209Jun 17 04:00 PM
Friedman Michael ADirectorJun 15Option Exercise0.0037500Jun 17 04:00 PM
BARKER RICHARD WDirectorJun 15Option Exercise0.001,125013,673Jun 17 04:00 PM
LOUGHLIN JAMES JDirectorJun 15Option Exercise0.002,441041,861Jun 17 04:00 PM
MARIO ERNESTDirectorJun 15Option Exercise0.00375062,884Jun 17 04:00 PM
CASEY MICHAEL DDirectorJun 15Option Exercise0.0037500Jun 17 04:00 PM
Haller Julia ADirectorJun 15Option Exercise0.0037502,409Jun 17 04:00 PM
Haller Julia ADirectorJun 14Option Exercise0.0030002,034Jun 17 04:00 PM
CASEY MICHAEL DDirectorJun 14Option Exercise0.0030000Jun 17 04:00 PM
MARIO ERNESTDirectorJun 14Option Exercise0.00300062,509Jun 17 04:00 PM
LOUGHLIN JAMES JDirectorJun 14Option Exercise0.00300039,420Jun 17 04:00 PM
Friedman Michael ADirectorJun 14Option Exercise0.0030000Jun 17 04:00 PM
BONNEY MICHAEL WDirectorJun 14Option Exercise0.0030001,834Jun 17 04:00 PM
BONNEY MICHAEL WDirectorJun 13Option Exercise0.0048401,534Jun 17 04:00 PM
Friedman Michael ADirectorJun 13Option Exercise0.0048400Jun 17 04:00 PM
LOUGHLIN JAMES JDirectorJun 13Option Exercise0.00484039,120Jun 17 04:00 PM
MARIO ERNESTDirectorJun 13Option Exercise0.00484062,209Jun 17 04:00 PM
CASEY MICHAEL DDirectorJun 13Option Exercise0.0048400Jun 17 04:00 PM
Haller Julia ADirectorJun 13Option Exercise0.0048401,734Jun 17 04:00 PM
CASEY MICHAEL DDirectorJun 03Option Exercise22.4724,666554,24524,666Jun 05 04:05 PM
Curran TerrieSEE REMARKSMay 02Option Exercise0.001,56309,483May 06 04:05 PM
VESSEY RUPERTSEE REMARKSMay 02Option Exercise0.006,731013,984May 06 04:05 PM
Alles Mark JCEO, CHAIRMAN OF BOARDMay 02Option Exercise0.0015,6080227,886May 06 04:05 PM
Biller JonathanEVP AND GENERAL COUNSELMay 02Option Exercise0.001,56304,674May 06 04:05 PM
AHMED NADIMPRES., HEMATOLOGY AND ONCOLOGYMay 02Option Exercise0.001,563013,124May 06 04:05 PM
Alles Mark JCEO, CHAIRMAN OF BOARDMar 01Option Exercise0.0033,8090226,178Mar 05 04:05 PM
LOUGHLIN JAMES JDirectorFeb 07Option Exercise22.4724,666554,24562,102Feb 11 04:05 PM
LOUGHLIN JAMES JDirectorFeb 07Sale87.2923,4662,048,32438,636Feb 11 04:05 PM
MARIO ERNESTDirectorDec 19Option Exercise59.068,600507,87363,013Dec 20 04:48 PM
Biller JonathanEVP AND GENERAL COUNSELDec 16Option Exercise0.001,90004,046Dec 18 06:45 PM
VESSEY RUPERTSEE REMARKSDec 16Option Exercise0.005,35009,887Dec 18 06:43 PM
Curran TerrieSEE REMARKSDec 16Option Exercise0.002,50009,151Dec 18 06:28 PM
AHMED NADIMPRES., HEMATOLOGY AND ONCOLOGYDec 16Option Exercise0.003,000013,038Dec 18 06:26 PM
Alles Mark JCEO, CHAIRMAN OF BOARDDec 16Option Exercise0.008,9290196,245Dec 18 06:25 PM
MARIO ERNESTDirectorNov 26Option Exercise59.0610,000590,55054,413Nov 28 04:05 PM
MARIO ERNESTDirectorAug 09Sale92.3212,0001,107,88844,413Aug 13 04:05 PM